Article
08 Aug 2025
Implications Of FDA's "Radical Transparency" Plan For Complete Response Letters
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
29 Jul 2025
FDA Begins To Accept Nominations For The Commissioner's National Priority Voucher Pilot Program
Article
14 Jul 2025
"False Claims Act Working Group" Signals Aggressive FCA Enforcement In Health Care And Life Sciences
Article
23 Jun 2025
FDA Announces Commissioner's National Priority Vouchers To Facilitate Expedited Access To Certain Drugs
Article
02 Jun 2025
AI, Medical Products & FDA, Part 3: AI In Drug & Device Commercialization (Podcast)
Article
04 Apr 2025
LDTs Are Not Devices Under The FDCA: Eastern District Of Texas Vacates FDA Final Rule On LDTs
Article
13 Feb 2025
"DOGE" Reportedly Accesses CMS Contracting And Payment Systems
Article
16 Jan 2025
FDA Finalizes Its SIUU Guidance: An Analysis Of The Key Changes From The 2023 Draft Guidance
Article
27 Dec 2024
Recent SEC Case Against Biotech Company Highlights The Intersection Between FDA Findings And SEC Enforcement
Article
17 Dec 2024
FDA Issues New Draft Guidance For Expedited Program For Serious Conditions — Accelerated Approval Of Drugs And Biologics
Article
10 Dec 2024
FDA LDT Final Rule Litigation — Status And What May Happen Next
Article
09 Dec 2024
LDT Final Rule Litigation — Status Of Pending Court Challenges And What May Happen Next
Article
15 Jul 2024
FDA Issues Revised Draft Guidance On Addressing Misinformation About Medical Devices And Prescription Drugs
Article
03 Jul 2024
Chevron Overturned: What Does It Mean For Life Sciences Companies?
Article
21 May 2024
FDA LDT Rule Raises Question Of Whether FDA Should Regulate Diagnostic Testing
Article
20 May 2024
What You Should Know About The FDA's New Final Rule On LDTs
Article
14 May 2024
What You Need To Know About The FDA Laboratory Developed Test Final Rule
Article
13 May 2024
FDA Intends To Regulate Many Clinical Labs As Medical Device Manufacturers: What You Need To Know About The Laboratory Developed Test Final Rule
Article
08 May 2024
Five Key Takeaways From FDA's Updated Draft Guidance On Biosimilars Promotion
Article
14 Mar 2024
EXPERT INSIGHTS—FDA Started A Process To 'Downclassify' Most High-Risk IVD Types: Here Is Why, (Mar 5, 2024)
